MASTOCHECK is a cancer diagnostic software that analyzes three types of patented breast cancer specific protein markers
with a mass spectrometer and substitutes the result into the algorithm provides a highly accurate indication of early breast cancer.
MASTOCHECK is conducted through a simple blood draw, providing high diagnostic accuracy through
the comprehensive analysis of multiple biomarkers specifically detected in breast cancer.
Under collaboration with domestic researchers, three proteins with specific changes in expression in breast cancer among
the proteins in the body were selected. The application of MASTOCHECK's proprietary AI algorithm has contributed to enhanced accuracy.
In January 2019, MASTOCHECK obtained medical device manufacturing approval from
the Ministry of Food and Drug Safety after demonstrating efficacy in breast cancer diagnosis for phases 0, 1, and 2. MASTOCHECK also acquired
New Excellent Technology (NET) certification from the Ministry of Health and Welfare in September 2019.
MASTOCHECK currently holds 10 patents in four countries, including Korea, the United States, China, and Japan.
Diagnosing early-stage
breast cancer (phases 0-2)
A simple test with
a small amount of blood
Safe in vitro diagnostic
medical device approved by
the Ministry of Food and
Drug Safety in South Korea
Visit to a hospital /
screening center &
Medical consultation
A small amount of
blood sampling
Send the blood to
MASTOCHECK
testing center
Analyze biomarkers
in the blood with
mass spectrometer
Entering biomarker values
into the patented diagnostic
algorithm to determine
onset of breast cancer
Receive the test result
and consult with
a medical specialist
This product is a medical device. Please read and follow the precautions and instructions for use carefully.
The test results using this product alone cannot determine the diagnosis and treatment methods for stages 0, 1, and 2 of breast cancer.
For the diagnosis of stage 3 and 4 of breast cancer, additional clinical diagnostic tests are required.
